Denali Therapeutics Inc.

DNLI

US24823R1059

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-06-29 pm EDT			After hours 07:56:10 pm
25.89 ^USD	+1.25%		25.18	-2.72%

Jun. 18	Denali Therapeutics Inc. Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for USD 195 Million	CI
Jun. 18	Denali Therapeutics to Sell its Rare Pediatric Disease Priority Review Voucher for $195 Million	MT

Takeda Ends Denali Therapeutics Dementia-Drug Partnership

Published on 04/03/2026 at 02:05 pm EDT - Modified on 04/03/2026 at 02:06 pm EDT

Dow Jones

DENALI THERAPEUTICS INC.

+1.25%

TAKEDA PHARMACEUTICAL COMPANY LIMITED

-0.33%

By Katherine Hamilton

Denali Therapeutics said Takeda Pharmaceuticals terminated the companies' agreement to co-develop and commercialize a dementia drug.

Denali would regain full ownership of DNL593, an investigational drug designed to treat frontotemporal dementia-granulin.

In 2018, Denali and Takeda entered into an option and collaboration agreement to develop and commercialize up to three specified therapeutic product candidates for neurodegenerative diseases.

Denali said it plans to report results from the continuing Phase 1/2 trial of DNL593 by the end of this year.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

04-03-26 1404ET

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Off-Hours Price	Change	5-day change	Capi.
	DENALI THERAPEUTICS INC.	25.89USD	+1.25%	+7.65%	4.11B
	TAKEDA PHARMACEUTICAL COMPANY LIMITED	5,159.00JPY	-0.33%	+2.91%	50.5B

Latest news about Denali Therapeutics Inc.

Jun. 18	Denali Therapeutics Inc. Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for USD 195 Million	CI
Jun. 18	Denali Therapeutics to Sell its Rare Pediatric Disease Priority Review Voucher for $195 Million	MT
Jun. 17	An undisclosed buyer entered into an asset purchase agreement to acquire Rare Pediatric Disease Priority Review Voucher of Denali Therapeutics Inc from Denali Therapeutics Inc. for a cash consideration of $195 million.	CI
Jun. 17	Denali Therapeutics Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 01:00 PM
Jun. 05	Denali Therapeutics Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-04-2026 08:45 AM
May. 26	Denali Therapeutics' Focus Shifts to Other Pipeline Assets After Phase 2b Study Failure, Morgan Stanley Says	MT
May. 22	Morgan Stanley Cuts Price Target on Denali Therapeutics to $35 From $40, Keeps Overweight Rating	MT
May. 22	Wall Street Packs for the Long Weekend
May. 22	Wedbush Cuts Price Target on Denali Therapeutics to $20 From $23, Keeps Outperform Rating	MT
May. 22	Deutsche Bank Adjusts Denali Therapeutics Price Target to $31 From $35, Maintains Buy Rating	MT
May. 22	Denali, Biogen Discontinue Parkinson's Drug Development Amid Phase 2 Setback; Shares Down Pre-Bell	MT
May. 21	Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study	RE
May. 21	Biogen Inc. and Denali Therapeutics Inc. Provide Update on Phase 2b LUMA Study Of BIIB122 In Early-Stage Parkinson?s Disease	CI
May. 14	Morgan Stanley Trims Price Target on Denali Therapeutics to $40 From $42, Keeps Overweight Rating	MT
May. 12	Denali Therapeutics Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 03:00 PM

Chart Denali Therapeutics Inc.

Duration

Period

DNLI: Dynamic Chart

Denali Therapeutics Inc. is a biopharmaceutical company establishing a new class of biotherapeutics designed to cross the blood-brain barrier using its TransportVehicle platform. It is focused on building a portfolio of therapeutic candidates by investing in its TV franchises, i.e., Enzyme TV (ETV), Oligonucleotide TV (OTV), and Antibody TV (ATV), to advance programs for rare diseases, such as lysosomal storage diseases, and common diseases, such as Alzheimer's disease and Parkinson's disease. Its most advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (Hunter syndrome). TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for mucopolysaccharidosis IIIA (Sanfilippo syndrome type A), DNL593 (PTV:PGRN) for frontotemporal dementia-granulin, DNL628 (OTV:MAPT) for Alzheimerâ€™s disease, and DNL952 (ETV:GAA) for Pompe disease. It is also pursuing opportunities in other disease areas including oncology.

Employees

507

Sector

Biotechnology & Medical Research

More about the company